Combining VIPS And ATUM To Accelerate Commercial Cell Line Manufacturing

In traditional cell line development campaigns, the number of clones to be screened is in the order of many thousands  to find the few gold nuggets, the high producers.In addition to being rare events, most of these clones carry rearranged, concatemerized forms of the recombinant insert leading to transgene fusions, and deletions.

Two important negative consequences of these undesired transgene structures are the unpredictable subunit ratios, potentially increasing the product related impurity levels, and, the increased probability of genetic instability.

The reduced clone screening burden (100-200 clones per project), due to the advantages of transposase-mediated stable integration, as well as the early and unequivocal monoclonality assurance with VIPS and Cell Metric instrumentation now facilitates the parallel execution of a large number of cell line development campaigns.